If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How do you treat a Mounjaro® (tirzepatide) overdose?
In the event of an overdosage, contact Poison Control for latest recommendations.
See important safety information, including boxed warning, in the attached prescribing information.
Approved Dosages
The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.1
After 4 weeks, increase the dosage to 5 mg once weekly.1
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.1
The maximum dose of tirzepatide is 15 mg once weekly.1
Overdose
In the event of an overdosage, contact Poison Control for latest recommendations.1
Appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.1
A period of observation and treatment for these symptoms may be necessary, considering the half-life of tirzepatide is approximately 5 days.1
Enclosed Prescribing Information
Reference
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: January 23, 2025